MiNK Therapeutics, Inc. 8-K

What Happened
MiNK Therapeutics filed an 8‑K (Item 5.02) announcing that, effective March 13, 2026, the Board appointed Melissa Orilall as Principal Financial Officer and Austin Charette as Principal Accounting Officer. Both executives are Agenus, Inc. employees and will provide services to MiNK under an Amended and Restated Intercompany Services Agreement with Agenus.

Key Details

• Effective date: March 13, 2026; 8‑K filed March 19, 2026, signed by CEO Jennifer S. Buell.
• Melissa Orilall (age 37): Vice President, Global Financial Operations at Agenus since Nov 2017; responsibilities include general accounting, month‑end and quarterly close, and FP&A. Canadian CPA; Honors BAS in Accounting, York University.
• Austin Charette (age 37): Senior Director, Financial Reporting & Compliance at Agenus (joined Aug 2017); prior auditor at Deloitte & Touche (2013–2017). Holds a BS in Computer Information Systems (Roger Williams) and MS Accounting and MBA (Northeastern).
• Compensation/arrangements: No new agreements or modifications with MiNK; neither receives direct compensation from MiNK — services are provided under the intercompany services agreement. Neither has family relationships or related‑party transactions requiring disclosure.

Why It Matters
These appointments place responsibility for MiNK’s financial operations, external reporting and internal controls with experienced Agenus finance personnel, formalizing outsourced/shared services rather than hiring in‑house executives. For investors, the filing signals continuity in financial leadership and that MiNK’s accounting and reporting functions are being managed through its intercompany arrangement with Agenus; there are no disclosed changes to compensation or related‑party arrangements that would immediately affect MiNK’s finances.